Krystal Biotech, Inc. (KRYS) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $1.23B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-4.33M; Retained Earnings (Accumulated Deficit)USD $134.86M.
- 2026-03-31: Common Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $1.20B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-1.62M; Retained Earnings (Accumulated Deficit)USD $80.09M.
- 2025-12-31: Common Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $1.19B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $1.14M; Retained Earnings (Accumulated Deficit)USD $24.16M.
- 2025-09-30: Common Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $1.16B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $1.10M; Retained Earnings (Accumulated Deficit)USD $-27.24M.
Krystal Biotech, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Preferred Stock, Value, Issued USD | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $1.23B | $-4.33M | $134.86M | $1.36B | 3 month · $15.29M | (m) | (m) | (m) |
| 2026-03-31 | $0.00 | $1.20B | $-1.62M | $80.09M | $1.28B | 3 month · $14.46M | (m) | (m) | (m) |
| 2025-12-31 | $0.00 | $1.19B | $1.14M | $24.16M | $1.22B | 12 month · $58.32M | (m) | (m) | (m) |
| 2025-09-30 | $0.00 | $1.16B | $1.10M | $-27.24M | $1.14B | 3 month · $14.21M | (m) | (m) | (m) |
| 2025-06-30 | $0.00 | $1.15B | $1.16M | $-106.60M | $1.04B | 3 month · $15.08M | (m) | (m) | (m) |
| 2025-03-31 | $0.00 | $1.13B | $390.00K | $-144.94M | $984.67M | 3 month · $14.45M | (m) | (m) | (m) |
| 2024-12-31 | $0.00 | $1.13B | $-190.00K | $-180.67M | $946.38M | 12 month · $52.39M | (m) | (m) | (m) |
| 2024-09-30 | $0.00 | $1.11B | $1.51M | $-226.15M | $885.85M | 3 month · $14.26M | (m) | (m) | (m) |
| 2024-06-30 | $0.00 | $1.09B | $-634.00K | $-253.33M | $838.89M | 3 month · $13.78M | (m) | (m) | (m) |
| 2024-03-31 | $0.00 | $1.07B | $-299.00K | $-268.89M | $799.24M | 3 month · $10.02M | (m) | (m) | (m) |
| 2023-12-31 | $0.00 | $1.05B | $638.00K | $-269.83M | $778.64M | 12 month · $41.18M | (m) | (m) | (m) |
| 2023-09-30 | $0.00 | $1.03B | $-382.00K | $-278.52M | $755.95M | 3 month · $8.72M | (m) | (m) | (m) |
| 2023-06-30 | $0.00 | $1.01B | $-236.00K | $-359.27M | $653.11M | 3 month · $11.44M | (m) | (m) | (m) |
| 2023-03-31 | $0.00 | $815.78M | $-154.00K | $-326.06M | $489.57M | 3 month · $10.60M | (m) | (m) | (m) |
| 2022-12-31 | $0.00 | $803.72M | $-728.00K | $-280.76M | $522.23M | 12 month · $33.78M | (m) | (m) | (m) |
| 2022-09-30 | $0.00 | $790.95M | $-1.48M | $-248.71M | $540.77M | 3 month · $9.20M | $0.00 | (m) | (m) |
| 2022-06-30 | $0.00 | $779.58M | $-1.54M | $-218.86M | $559.18M | 3 month · $8.34M | $0.00 | (m) | (m) |
| 2022-03-31 | $0.00 | $740.50M | $-1.20M | $-190.75M | $548.55M | 3 month · $6.57M | $0.00 | (m) | (m) |
| 2021-12-31 | $0.00 | $734.52M | $-163.00K | $-140.78M | $593.58M | 12 month · $15.60M | $0.00 | (m) | (m) |
| 2021-12-03 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $227.00K |
| 2021-09-30 | $0.00 | $527.23M | $-14.00K | $-118.98M | $408.24M | 3 month · $3.75M | $0.00 | (m) | (m) |
| 2021-06-30 | $0.00 | $521.95M | $-21.00K | $-103.39M | $418.54M | 3 month · $4.26M | $0.00 | (m) | (m) |
| 2021-03-31 | $0.00 | $517.67M | $3.00K | $-87.03M | $430.65M | 3 month · $2.35M | $0.00 | (m) | (m) |
| 2021-02-01 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $198.00K |
| 2020-12-31 | $0.00 | $363.29M | $6.00K | $-71.21M | $292.08M | 12 month · $3.31M | $0.00 | (m) | (m) |
| 2020-09-30 | $0.00 | $362.53M | $20.00K | $-60.83M | $301.72M | 3 month · $1.36M | $0.00 | (m) | (m) |
| 2020-06-30 | $0.00 | $360.88M | $40.00K | $-51.22M | $309.70M | 3 month · $807.00K | $0.00 | (m) | (m) |
| 2020-03-31 | $0.00 | $242.73M | $24.00K | $-44.39M | $198.37M | 3 month · $539.00K | $0.00 | (m) | (m) |
| 2019-12-31 | $0.00 | $241.95M | $10.00K | $-39.05M | $202.91M | 12 month · $1.24M | $0.00 | (m) | (m) |
| 2019-09-30 | $0.00 | $241.32M | $11.00K | $-33.69M | $207.65M | 3 month · $278.00K | $0.00 | (m) | (m) |
| 2019-06-30 | $0.00 | $227.69M | $18.00K | $-29.42M | $198.29M | 3 month · $325.00K | $0.00 | (m) | (m) |
| 2019-03-31 | $0.00 | $133.54M | $16.00K | $-24.07M | $109.49M | 3 month · $313.00K | $0.00 | (m) | (m) |
| 2018-12-31 | $0.00 | $133.18M | $2.00K | $-19.96M | $113.23M | 12 month · $792.00K | $0.00 | (m) | (m) |
| 2018-09-30 | $0.00 | $68.54M | $1.00K | $-16.25M | $52.29M | 3 month · $279.00K | (m) | (m) | (m) |
| 2018-06-30 | $0.00 | $58.77M | $-2.00K | $-13.50M | $45.27M | 3 month · $146.00K | (m) | (m) | (m) |
| 2018-03-31 | $0.00 | $58.62M | (m) | $-11.22M | $47.40M | 3 month · $65.00K | (m) | (m) | (m) |
| 2017-12-31 | $0.00 | $58.54M | (m) | $-9.07M | $49.47M | (m) | (m) | 12 month · $3.16M | (m) |
| 2017-09-30 | $0.00 | $57.88M | (m) | $-7.68M | $50.20M | (m) | (m) | (m) | (m) |
| 2016-12-31 | $0.00 | $33.00K | (m) | $-1.15M | $289.00K | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |